Psychiatric Condition News and Research

RSS

Grieving patients treated with talk therapy have lower risk of suicide and psychiatric illness

In a comprehensive study, researchers from Aarhus University show that grieving patients who receive what is known as talk therapy at the general practitioner shortly after a relative's death, have a lower risk of suicide and psychiatric illness than others.

20 Sep 2018

Collaborative care models have proven to improve outcomes and access to mental health care

Mental health has been in the news recently for all the wrong reasons, from unexpected celebrity suicides to a reported increase in depression diagnoses.

23 Jul 2018

Study finds factors underlying current rise in radicalization among European youth

A study published in European Psychiatry reports on factors underlying the current rise in radical conversions among European youth.

21 Jun 2018

Community health centers caught in ‘Washington’s political dysfunction’

As lawmakers face another deadline this week for passing legislation to keep the federal government open, one of the outstanding issues is long-term funding for a key health care safety-net program.

5 Feb 2018

People with OCD show distinct changes in the brain when treated with special form of talk therapy

UCLA researchers report that people with obsessive-compulsive disorder, when treated with a special form of talk therapy, demonstrate distinct changes in their brains as well as improvement in their symptoms.

19 Sep 2017

Funding cuts damaging young people's access to mental health services, say researchers

Funding cuts and austerity measures are damaging young people's access to mental health services, with potentially long-term consequences for their mental wellbeing, say researchers at the University of Cambridge.

15 Sep 2017

New study shows link between marijuana use and psychotic-like experiences

Going from an occasional user of marijuana to a weekly or daily user increases an adolescent's risk of having recurrent psychotic-like experiences by 159%, according to a new Canadian study published today in the Journal of Child Psychology and Psychiatry.

5 Jul 2017

Personalized approach to pharmacotherapy may provide advances in treatment of panic disorders

Although drug therapy is the accepted first-line treatment for panic disorders, 17% to 64% of patients do not respond adequately and continue to exhibit one of the most common symptoms of PD, the panic attack.

26 Apr 2017

Salk scientists develop new way to find responders to lithium therapy

For roughly one-third of people diagnosed with bipolar disorder, lithium is a miracle drug, effectively treating both their mania and depression. But once someone is diagnosed, it can take up to a year to learn whether that person will be among the 30 percent who respond to lithium or the 70 percent who do not.

21 Mar 2017

Online program for insomnia can improve amount and quality of sleep

An online program designed to help people overcome insomnia significantly improves both the amount and quality of sleep, a new study has found.

1 Dec 2016

Study shows non-Hispanic blacks less likely to receive treatment for schizophrenia

Non-Hispanic blacks are almost twice as likely as non-Hispanic whites to be diagnosed with schizophrenia, but they're significantly less likely to receive medication for treatment, according to researchers.

18 May 2016

Toxoplasmosis infection may be linked to rage disorder

A new study has shown that people who have a psychiatric condition called intermittent explosive disorder (IED) are twice as likely to have been exposed to toxoplasma gondii, the parasite found in cat feces and undercooked meat.

24 Mar 2016

Review of EAS cases among patients with psychiatric conditions in the Netherlands

A review of euthanasia or assisted suicide (EAS) cases among patients with psychiatric disorders in the Netherlands found that most had chronic, severe conditions, with histories of attempted suicides and hospitalizations, and were described as socially isolated or lonely, according to an article published online by JAMA Psychiatry.

11 Feb 2016

Palatin achieves patient enrollment target in pivotal phase 3 studies of bremelanotide for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced it has achieved its patient enrollment target in its two pivotal phase 3 clinical studies of bremelanotide for the treatment of female sexual dysfunction (FSD).

10 Dec 2015

Treating insomnia through a CBT device? An interview with Dr Ebrahim

Insomnia refers to a clinical condition that is characterised by one or more of the following – difficulty initiating sleep and/or maintaining sleep and/or waking up too early AND associated with symptoms the next day such as sleepiness, lethargy, loss of concentration.

16 Nov 2015

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Sprout Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.

19 Oct 2015

Valeant enters into definitive agreement to acquire Sprout Pharmaceuticals

Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.

20 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

Children with psychiatric issues more likely to have serious problems as adults

Children with even mild or passing bouts of depression, anxiety and/or behavioral issues were more inclined to have serious problems that complicated their ability to lead successful lives as adults, according to research from Duke Medicine.

16 Jul 2015

New UCLA study finds Naltrexone drug as promising treatment for methamphetamine addiction

A new study by UCLA researchers has found that Naltrexone, a drug used to treat alcoholism, may also be a promising treatment for addiction to methamphetamine.

19 May 2015